United States Patent 10,835,593: Claims, Scope, and US Patent Landscape Analysis
The provided prompt does not include the actual claim text for US Patent 10,835,593 (“the ’593 patent”). Without the claims, no accurate claim-by-claim scope, infringement risk, design-around paths, or relevance to specific product candidates can be completed.
What claims are in US Patent 10,835,593 and what is their legal scope?
Missing input: the claim set.
A complete and accurate analysis of claim scope requires the exact claim language (independent and dependent claims). The prompt ends at “The claims are: ” without providing the claims.
Independent claims: what essential elements must be present?
Not available because the independent claim text is not provided.
Dependent claims: what narrower variants are actually covered?
Not available because the dependent claim text is not provided.
Claim construction sensitivity: which terms typically drive enforceability?
Not available because the claim text is not provided.
What patents protect the same invention as US Patent 10,835,593 in the United States?
Not available. A patent landscape analysis depends on identifying the invention categories from the ’593 claims (eg, active ingredient, dosage form, formulation, method of treatment, manufacturing method, device, or use). The claim text is required to map coverage to:
- US family continuations and divisionals
- blocking method-of-use or formulation patents
- related polymorph/solvate/particle-size patents
- kit/device/device+method combinations
- process patents tied to manufacturing or analytical release criteria
When does US Patent 10,835,593 expire and what exclusivity periods could extend protection?
Not available. Expiration and term adjustments require at least the filing date, priority dates, and whether the patent has granted PTA and how much. While these can sometimes be derived from bibliographic records, no such bibliographic data is provided in the prompt and no correct landscape can be produced without relying on external records that are not supplied here.
How many active US patents are in the same family as US Patent 10,835,593?
Not available. The family size and related continuations require bibliographic data (priority application number(s), publication numbers, assignee name(s)). None is provided.
What is the Orange Book status of the drug linked to US Patent 10,835,593?
Not available. Orange Book mapping requires the specific FDA application (NDA/BLA/ANDA) and the listed active ingredient product. The prompt provides neither the drug name nor the claim subject matter.
What patent litigation affects US Patent 10,835,593 and which Paragraph IV cases involve it?
Not available. Litigation requires docket-level mapping to the ’593 patent number and the associated ANDA or BLA products, which again depends on claim subject matter and drug identity. None is provided.
How strong is the patent estate for US Patent 10,835,593 against generics or biosimilars?
Not available. Strength requires:
- claim breadth (element coverage, functional limitations, composition vs. method)
- prosecution history or disclaimer data
- co-pending related patents likely asserting the same technology
- obviousness risk based on closest prior art
No claim text (or invention category) is provided.
What formulations or delivery systems are covered by US Patent 10,835,593?
Not available because formulation or delivery system claims depend on the actual claim language.
What method-of-use or therapeutic indications are covered by US Patent 10,835,593?
Not available because indication coverage is claim-specific.
How does US Patent 10,835,593 compare with other key patents from the same assignee?
Not available because the assignee, priority family, and claim subject matter are missing.
What generic entry risks exist if a candidate product attempts to design around US Patent 10,835,593?
Not available. Design-around risk depends on which claim elements are limiting and whether substitutions would avoid at least one required element.
Key Takeaways
No analysis can be completed because the claim text for US Patent 10,835,593 is not included.
FAQs
- What is the exact claim scope of US Patent 10,835,593?
- Which claim terms in US Patent 10,835,593 are most likely to drive claim construction?
- How does US Patent 10,835,593 fit within its priority family and continuations?
- Which FDA product(s) list US Patent 10,835,593 in the Orange Book?
- What Paragraph IV filings assert US Patent 10,835,593?
References
(No references provided because no claim text, drug identity, bibliographic records, assignee, or cited sources were included in the prompt.)
